ConductScience.org, home

Paper9060552

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Brice P and 9 others. J Clin Oncol, 1997. Cited by 527 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Papers, record 9060552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9060552

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
PubMed
Journal
J Clin Oncol
PubMed
Year
1997
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
527
iCite
Relative citation ratio, by iCite
11.5
iCite
Revised in PubMed
2017-02-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brice PP
2Bastion YY
3Lepage EE
4Brousse NN
5Haïoun CC
6Moreau PP
7Straetmans NN
8Tilly HH
9Tabah II
10Solal-Céligny PP

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Antineoplastic Agents, AlkylatingMajor topic
Interferon-alphaMajor topic
Lymphoma, FollicularMajor topic
Adult
Aged
Disease Progression
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Prednimustine
Prospective Studies

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03823365Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaBackground

Cited by244

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 527 citations.

PMIDTitleJournalYearIn PapersSource
42,979,489Low tumor burden follicular lymphoma: The state of the art.Hemasphere2026https://conductscience.org/library/papers/42979489PubMed
42,903,357Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.Hemasphere2026https://conductscience.org/library/papers/42903357PubMed
42,657,590LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.Br J Haematol2026https://conductscience.org/library/papers/42657590PubMed
42,645,356Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.Curr Oncol2026https://conductscience.org/library/papers/42645356PubMed
42,591,708Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass.IJU Case Rep2026https://conductscience.org/library/papers/42591708PubMed
42,553,584First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.Hemasphere2026https://conductscience.org/library/papers/42553584PubMed
42,527,721Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Curr Oncol Rep2026https://conductscience.org/library/papers/42527721PubMed
41,949,430Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.Br J Haematol2026https://conductscience.org/library/papers/41949430PubMed
41,799,792Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.Case Rep Hematol2026https://conductscience.org/library/papers/41799792PubMed
41,779,695Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.PLoS One2026https://conductscience.org/library/papers/41779695PubMed
41,710,665Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP.Front Oncol2026https://conductscience.org/library/papers/41710665PubMed
41,681,868Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.Cancers (Basel)2026https://conductscience.org/library/papers/41681868PubMed
41,634,892Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study.J Pharm Health Care Sci2026https://conductscience.org/library/papers/41634892PubMed
41,329,901FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.J Clin Oncol2026https://conductscience.org/library/papers/41329901PubMed
41,323,446Transformation of Primary Small Intestinal Follicular Lymphoma to CD20-Negative Diffuse Large B-Cell Lymphoma following Rituximab Treatment: A Case Report.Case Rep Gastroenterol2025https://conductscience.org/library/papers/41323446PubMed
41,283,583Trousseau's Syndrome and Marantic Endocarditis in a Patient with Pulmonary Adenocarcinoma: A Case Report and a Brief Review of the Literature.Reports (MDPI)2025https://conductscience.org/library/papers/41283583PubMed
41,114,104Colorectal follicular lymphoma: A single-center retrospective study.World J Gastrointest Oncol2025https://conductscience.org/library/papers/41114104PubMed
41,058,067Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective.Hematol Oncol2025https://conductscience.org/library/papers/41058067PubMed
40,994,345Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.Haematologica2026https://conductscience.org/library/papers/40994345PubMed
40,966,421Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.Blood Adv2025https://conductscience.org/library/papers/40966421PubMed

See all 244 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9060552

GET https://conductscience.org/api/papers/v1/9060552/cited_by?page=2